Zydus group's Cadila Healthcare hopes to launch its version of Gilead Sciences’ investigational COVID-19 drug remdesivir in India by end-July, even as other early licensees Cipla and Hetero Drugs have just introduced the formulation in the country. Marketing approval for Zydus Cadila's brand of remdesivir is expected by mid-July.
Meanwhile, the company’s other COVID-19 candidates - a DNA vaccine and pegylated interferon alpha-2b - are also being fast-tracked.




